Dimopoulos et al reported criteria for describing the change in renal function in response to therapy for multiple myeloma. The authors are from multiple institutions in the United States and Europe participating in the International Myeloma Working Group (IMWG).
Patient selection: myeloma with estimated GFR < 50 mL per minute per 1.73 square meter BSA at baseline
|
eGFR in mL per min per 1.73 sq m BSA |
Reduction in GFR |
Stage of Renal Impairment |
|
30 to 59 |
moderate |
3 |
|
15 to 29 |
severe |
4 |
|
< 15 or on dialysis |
renal failure |
5 |
Parameters:
(1) baseline estimated in GFR in mL per min per 1.73 square meter BSA
(2) best estimated in GFR after therapy, in mL per min per 1.73 square meter BSA
|
Baseline eGFT |
eGFR after Therapy |
Interpretation |
|
< 50 |
>= 60 |
complete response |
|
15 to 29 |
30 to 59 |
minor response |
|
< 15 or on dialysis |
30 to 59 |
partial response |
|
< 15 or on dialysis |
15 to 29 |
minor response |
A change was considered sustained if it persisted for >= 2 months.
The above table left various gaps, which might be filled as follows.
|
Baseline eGFT |
eGFR after Therapy |
Interpretation |
|
30 to 49 |
30 to 59 |
unchanged |
|
30 to 49 |
< 30 |
progression |
|
15 to 29 |
15 to 29 |
unchanged |
|
15 to 29 |
< 15 |
progression |
|
< 15 or on dialysis |
< 15 or on dialysis |
unchanged |
When describing a change between 2 values, an increase > 10% is termed an increase, a decline > 10% is termed a decrease, else unchanged.
Specialty: Nephrology, Clinical Laboratory
ICD-10: ,
